Summary: Inflammation is the body’s natural defense, but when it gets stuck in the “on” position, it drives everything from sepsis to Alzheimer’s. A comprehensive review identifies a protein called TREM-1 (Triggering Receptor Expressed on Myeloid cells-1) as a central “amplifier” of these harmful immune responses.
Found on key immune cells like macrophages and neutrophils, TREM-1 doesn’t just start inflammation—it supercharges it. The study highlights TREM-1 as a premier therapeutic target, offering a potential “universal key” to treating diverse conditions like rheumatoid arthritis, gout, and neurodegenerative diseases.
Key Facts
- The Multiplier Effect: TREM-1 works by partnering with an adaptor protein called DAP12. Together, they engage in “crosstalk” with Toll-like receptors, creating a massive surge in innate immune signaling.
- A Marker for Mortality: In cases of sepsis, levels of “soluble TREM-1” in the blood are so closely linked to the body’s inflammatory storm that they directly correlate with patient mortality rates.
- Neuroinflammation Link: The review connects TREM-1 on microglia (the brain’s immune cells) to the progression of Alzheimer’s and Parkinson’s, suggesting that “quieting” this receptor could slow brain-cell death.
- New Drug Frontier: Several experimental antagonists—including LR12, LP17, GF9, and a clinical-stage nanobiotide—have successfully reduced joint inflammation and sepsis symptoms in preclinical models.
- The Balancing Act: While TREM-1 inhibition is promising, researchers warn of “immunosuppression risks.” The goal is to dampen the hyper-inflammatory response without leaving the patient defenseless against common infections.
Source: Far Publishing Ltd
Published in Current Molecular Pharmacology, a comprehensive review by Eman R. Al Sawy and colleagues from Cairo University consolidates evidence on the triggering receptor expressed on myeloid cells-1 (TREM-1) as a central amplifier of inflammatory responses.
The authors explain that TREM-1, primarily expressed on macrophages, monocytes, and neutrophils, potently enhances innate immune signaling through its adaptor protein DAP12 and crosstalk with Toll-like receptors.
“Dysregulated TREM-1 activation is increasingly implicated in both acute and chronic inflammatory conditions, yet effective targeted therapies remain limited,” said corresponding author Nesrine S. El Sayed.
The review covers TREM-1’s pathogenic role in sepsis, where elevated soluble TREM-1 correlates with mortality; in arthritis, where TREM-1 inhibition reduces joint inflammation; and in neurodegenerative diseases like Alzheimer’s and Parkinson’s, where microglial TREM-1 contributes to neuroinflammation.
Several antagonists—including LR12, LP17, GF9, and the clinical-stage nanobiotide—have shown promise in preclinical models. However, the authors caution that species differences, disease heterogeneity, and risks of immunosuppression require careful optimization.
They conclude that TREM-1-directed therapies hold translational potential, particularly for patients with sepsis, rheumatoid arthritis, gout, and Alzheimer’s disease, and call for well-designed clinical trials to define therapeutic windows and identify responsive patient subgroups.
Key Questions Answered:
A: It’s an evolutionary survival tool. When you have a massive infection, you want your immune system to hit back hard and fast. TREM-1 provides that “boost.” The problem arises in modern chronic diseases where the amplifier stays cranked to 11 long after the “intruder” is gone, causing the body to attack its own tissues.
A: Potentially! Because TREM-1 is a fundamental part of the myeloid immune response (found in both the joints and the brain’s microglia), a drug that blocks it could theoretically dampen inflammation across different organs. It’s a “one-stop-shop” approach to precision medicine.
A: We are in the “translational” phase. While results in the lab (preclinical) are very strong, the “nanobiotide” mentioned is currently in clinical stages. The next big hurdle is human trials to ensure the drugs don’t accidentally shut down the entire immune system while trying to fix the inflammation.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by our staff.
About this genetics and neuroinflammation research news
Author: Chris Zhou
Source: FAR Publishing Limited
Contact: Chris Zhou – FAR Publishing Limited
Image: The image is credited to Neuroscience News
Original Research: Open access.
“TREM-1 receptor: A key player in inflammatory diseases” by Eman R. Al Sawy, Mona M. Saber, Noha N. Nassar, and Nesrine S. El Sayed. Current Molecular Pharmacology
DOI:10.1016/j.cmp.2026.03.002
Abstract
TREM-1 receptor: A key player in inflammatory diseases
Triggering receptor expressed on myeloid cells-1 (TREM-1) is a cell-surface receptor primarily expressed on myeloid cells, including macrophages, monocytes, and neutrophils, where it functions as a potent amplifier of innate immune responses.
Dysregulated TREM-1 activation has been increasingly implicated in the pathogenesis of both acute and chronic inflammatory conditions, including sepsis, inflammatory arthritis, and neurodegenerative diseases.
Despite advances in supportive care, effective targeted therapies that modulate excessive inflammation remain limited, particularly in sepsis and neuroinflammatory disorders.
Recent preclinical and emerging clinical evidence highlight TREM-1 as a promising therapeutic target and soluble TREM-1 as a potential biomarker for disease severity and prognosis.
This review provides an updated overview of TREM-1 biology, its signalling pathways, and its pathogenic role in sepsis, arthritis, and neurodegenerative diseases, with a particular focus on recent advances in TREM-1-targeted therapeutic strategies and their translational relevance.
